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012.05.0Abstract Global risk scores use individual level information on non-modiﬁable risk factors (such
as age, sex, ethnicity and family history) and modiﬁable risk factors (such as smoking status and
blood pressure) to predict an individual’s absolute risk of an adverse event over a speciﬁed period
of time in the future. Cardiovascular risk scores have two major uses in practice. First, they can be
used to dichotomise people into a group whose baseline risk, and therefore potential absolute ben-
eﬁt, is sufﬁciently high to justify the costs and risks associated with an intervention (whether treat-
ment or prevention) and a group with a lower absolute risk to whom the intervention is usually
denied. Second, they can be used to assess the effectiveness of an intervention (such as smoking ces-
sation or antihypertensive treatment) at reducing an individual’s risk of future adverse events. In
this context, they can be helpful in informing patients, motivating them to change their lifestyle,
and reinforcing the importance of continued compliance.
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Our understanding of how best to measure and respond to risk
has evolved over a number of years. Historically, individual
risk factors were measured and managed in isolation, but this
has been replaced by the adoption of global risk scores that
calculate overall risk based on a range of risk factors. Also,
the opportunistic use of risk scores among people who present
to healthcare workers has been replaced by increased use of
either mass screening or targeted screening of at-risk popula-
tions in an effort to identify unmet need and reduce health
inequalities. The integration of risk calculators into adminis-
trative software packages and online access has made risk
scores readily accessible to all general practitioners in the
UK.1 The scope of risk scores has recently widened beyond
coronary heart disease to other conditions, such as heart fail-
ure and diabetes mellitus. Also, as new biomarkers for cardio-
vascular disease have been identiﬁed, there have been an
increasing number of studies examining whether they can
add value to existing risk scores. Finally, as investigators have
identiﬁed genetic loci associated with cardiovascular condi-
tions, studies have started to address whether they could play
a role in risk prediction, either in isolation or combined with
traditional risk factors.
Our approach to evaluating the performance of risk scores
has also evolved over time. Initially, methods were adopted
from the assessment of screening tests, using measures of dis-
crimination such as sensitivity and speciﬁcity. As many predic-
tive models could be expressed as continuous variables, interest
grew in assessing the performance of predictive models across
the whole range of values. This was achieved by plotting sensi-
tivity versus 1-speciﬁcity for all values to produce a receiver
operating characteristic (ROC) curve. The area under the
ROC curve, also referred to as the c statistic, ranges from 0.5
(no predictive ability) to 1.0 (perfect discrimination). For use
in clinical or public health practice, a continuous measure of
risk needs to be reduced to two or more categories, but the
ROC plot can be useful in determining the best cut-off values
to apply. More recently, investigators have used reclassiﬁcation
between different risk groups to compare the discriminatory
performance of different risk scores. Results can be presented
simply as the total percentage of patients reclassiﬁed into a dif-
ferent risk group, but the preferred measure is the net reclassi-
ﬁcation index, which is calculated from: (proportion of cases
moving up – proportion of cases moving down) – (proportion
of controls moving up – proportion of controls moving down).2. One hundred and ten ways to measure risk!
Historically, cardiovascular risk scores have focused on coro-
nary heart disease; either predicting the risk of adverse events
in the general population or among patients with established
disease such as those presenting with acute coronary syn-
dromes. There are now 110 different cardiovascular risk scoresthat have been developed for use in the general population.2
More recent risk scores, such as ASSIGN (ASsessing cardio-
vascular risk using SIGN) and QRISK (QRESEARCH car-
diovascular risk algorithm), have differed from earlier scores
by incorporating socioeconomic deprivation and family his-
tory into the measurement of global risk.3–5 As a result, they
have been able to overcome some of the limitations of earlier
risk scores, which tended to introduce socioeconomic bias into
the detection and treatment of cardiovascular risk.4 However,
the performance of all risk scores is dependent on ready access
to complete and accurate data. In a recent study, in which they
applied six risk scores to routine general practice data, de la
Iglesia and colleagues4 highlighted missing data as a concern,
especially in relation to family history.
Knowledge of risk scores can translate into improved pre-
scribing and reduced risk.6 However, in a recent systematic re-
view, Liew and colleagues7 highlighted a number of problems
in the development of risk scores including a lack of standardi-
sation in the measurement of risk predictors and outcomes,
and failure of most studies constructing new risk scores to take
account of individuals who are already taking medications that
modify risk measurement, such as antihypertensive and lipid-
lowering agents. The latter may be misleading because primary
prevention should, ideally, be directed at individuals before the
development of risk factors and the occurrence of premature
disease. One of the limitations of existing risk scores based
on events over a ﬁxed period of time, commonly 10 years, is
that the score is heavily inﬂuenced by age. Therefore, young
individuals are unlikely to reach the threshold for intervention
irrespective of their current and future risk factors. One ap-
proach to identifying the subgroup of young people at in-
creased risk is to use lifetime risk rather than risk over a
ﬁxed period. Hippisley-Cox and colleagues8 recently compared
the use of QRisk2 reported as the lifetime risk of cardiovascu-
lar disease (in terms of age-sex speciﬁc centiles) with it reported
as risk over a 10-year period. The former identiﬁed a greater
proportion of younger individuals as being at risk of future
events. It also classiﬁed a greater proportion of individuals
from ethnic minority groups and with a positive family history
as being at risk of future cardiovascular events. Both factors
are associated with an increased risk of premature cardiovas-
cular events. While early identiﬁcation and prevention are
the ideal, the unselected screening of a younger population
may, nonetheless, be less cost-effective.
The application of risk scores to patients presenting with
acute coronary syndrome is now well established in both re-
search and clinical practice. In a recent Education in Heart pa-
per, Bueno and Fernandez-Aviles9 reviewed 11 risk scores
developed for the prediction of adverse events following acute
coronary syndrome. Of these, the GRACE (Global Registry
of Acute Coronary Events) and TIMI (Thrombolysis in Myo-
cardial Infarction) risk scores have been most widely adopted.
Fox and colleagues10 recently reviewed the extent to which the
GRACE risk score has been validated and adopted since ﬁrst
developed in 2003. To date, the GRACE risk score has been
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500 patients with acute coronary syndrome, ST-segment eleva-
tion myocardial infarction or non-ST-segment elevation myo-
cardial infarction. The risk score is easy to use in a clinical
setting and performs well when compared with other risk
scores. Therefore, it has been incorporated into many guide-
lines including those produced by the European Society of Car-
diology, American College of Cardiologists, American Heart
Association, Scottish Intercollegiate Guidelines Network and
National Institute for Health and Clinical Excellence.
3. Where next for risk scores?
Attention is now focusing on expanding the use of risk scores be-
yond coronary heart disease. Two recent studies have developed
risk scores for use in patientswith heart failure. TheHF––Action
(Heart Failure: A Controlled Trial Investigating Outcomes of
Exercise TraiNing) risk score was developed using a cohort of
patients with chronic heart failure and systolic dysfunction.11
The risk score was derived from information on exercise dura-
tion, serum urea nitrogen, body mass index and sex, and per-
formed well at predicting all-cause death within 1-year of
follow-up. Nineteen per cent of patients in the top decile for risk
score died, compared with 2% in the bottom decile. The score
had a c statistic of 0.73. TheGWTG––HR (GetWithTheGuide-
lines––Heart Failure) risk score was developed using a cohort of
patients hospitalised with heart failure.12 The component fac-
tors included age, systolic blood pressure, blood urea nitrogen,
heart rate, sodium, concomitant chronic obstructive pulmonary
disease and race. The risk of in-hospital death ranged from0.4%
to 9.7% across the risk score deciles and performed well among
both patients with preserved and impaired left ventricular sys-
tolic function with a c statistic of 0.75 in both groups.
Due to the rising prevalence of type II diabetes, there has
been increased awareness of the need to target screening and
prevention efforts at people with this condition. Van Dieren
et al.13 undertook a systematic review of studies published be-
tween 1966 and 2011 that had developed cardiovascular risk
scores suitable for use in patients with type II diabetes mellitus.
Of the 45 scores identiﬁed, only 12 were originally constructed
from a cohort of individuals with diabetes and only two of
these were restricted to patients in whom diabetes had been re-
cently diagnosed. Only nine studies reported the c statistic. Six
scores had undergone internal validation, using bootstrapping
or a split sample, and six had been subjected to external vali-
dation. Two studies had neither internal nor external valida-
tion. The authors identiﬁed an additional 33 scores that were
constructed from the general population but included diabetes
as a predictive factor. Only 12 had internally validated their
risk score using a split sample, cross-validation or bootstrap-
ping, and only eight had been externally validated in a popu-
lation with diabetes. Given the increasing prevalence of type
II diabetes and its increasing contribution to cardiovascular
disease, further research is required in this area.
4. Do biomarkers add value?
Several recently published studies have examined whether the
addition of biomarkers improved the performance of risk
scores in the general population. A common focus of these
studies has been trying to achieve better discrimination withinthe subgroup of individuals currently classiﬁed as having inter-
mediate risk (10–20% risk of an adverse event over 10 years).
Melander and colleagues14 evaluated the added value of a pa-
nel of biomarkers, C-reactive protein (CRP), cystatin C, lipo-
protein-associated phospholipase A2 (Lp-PLA2), mid-regional
pro-adre-nomedullin (MR-proADM), mid-regional pro-atrial
natriuretic peptide and N-terminal pro-B-type natriuretic pep-
tide (NT-proBNP), in predicting incident cardiovascular
events in a Swedish population cohort. There was a non-signif-
icant increase in the c statistic. In relation to predicting cardio-
vascular events, 8% were reclassiﬁed overall but only 1% were
moved into the high-risk category. There was no net reclassiﬁ-
cation. Among the intermediate risk group, the addition of
biomarkers resulted in reclassiﬁcation of 16% in terms of their
risk of cardiovascular events, but only 3% were moved into the
high-risk group. The net reclassiﬁcation improvement was
7.4%. Therefore, the improvements in classiﬁcation were lar-
gely achieved by down-grading, rather than identifying a great-
er proportion of high-risk individuals.
Rana and colleagues15 examined the added value of a series
of individual biomarkers in the UK population in predicting
coronary events: CRP, myeloperoxidase, paraoxonase, group
IIA secretory phospholipase A2, Lp-PLA2, ﬁbrinogen, macro-
phage chemoattractant protein 1 and adiponectin. Reclassiﬁ-
cation was the greatest for CRP, the addition of which
resulted in 12% net reclassiﬁcation improvement overall and
28% in the intermediate group. Zethelius and colleagues16
examined the added value of four biomarkers (troponin I,
NT-proBNP, cystatin C and CRP) when applied to a popula-
tion cohort of elderly Swedish men. The addition of all four
biomarkers signiﬁcantly increased the c statistic from 0.66 to
0.77. They reported a 26% net improvement in reclassiﬁcation
overall. The studies to date suggest that biomarker assays may
improve discrimination when added to existing risk scores.
However, their use has cost and logistical implications, partic-
ularly if risk scores are applied on a wide scale. Further re-
search is needed on the cost-effectiveness of adding
biomarkers to existing risk scores, particularly in relation to
general population screening.
Lorgis and colleagues17 demonstrated that adding NT-
proBNP to the GRACE risk score can improve its prognostic
value among patients presenting with acute coronary syn-
drome. Patients with both a high GRACE risk score and high
NT-proBNP level had a 50% risk of dying within 1 year of fol-
low-up. This was sixfold higher than the referent group. NT-
proBNP was found to be a useful addition across all age
groups but not in obese patients, in whom NT-proBNP levels
were much lower.18 Similar ﬁndings were reported when tropo-
nin and brain natri- uretic peptide were used in addition to the
TIMI risk score.19 Their addition produced only a slight in-
crease in the c statistic but, as with NT-proBNP, they were
able to identify a subgroup of the TIMI high-risk group who
were at very high risk of adverse events, and in whom an
aggressive approach to drug therapy and interventions might
be warranted.18 Damman and colleagues20 examined a cohort
of patients undergoing primary percutaneous coronary inter-
vention (PCI) for ST-segment elevation myocardial infarction.
They demonstrated that the addition of biomarkers (glucose,
NT-proBNP and estimated glomerular ﬁltration rate) im-
proved the prediction of mortality, resulting in signiﬁcant
improvements in net reclassiﬁcation (49%, p< 0.001) and
integrated discrimination (3%, p< 0.01).
8 J.P. PellRisk scores, such as CHADS2––VASC2, can predict the
risk of cerebrovascular events among patients with atrial ﬁbril-
lation, and are used to inform clinical decisions on the use of
anticoagulant therapy. A number of biomarkers have now
been identiﬁed that are associated with the incidence and prog-
nosis of atrial ﬁbrillation. In a recent review paper, Brugts and
colleagues21 highlighted the need for further research to deter-
mine whether the use of these biomarkers may improve the
existing risk scores and whether they offer the potential for risk
prediction at an earlier stage by identifying patients at risk of
developing atrial ﬁbrillation or at risk of progressing from the
subclinical to permanent stage of the condition.
Many pathophysiological mechanisms contribute to the
development of heart failure. Avellino and colleagues22 re-
viewed recently identiﬁed biomarkers associated with the rele-
vant pathways. They concluded that the biomarkers currently
showing most promise, in terms of risk stratiﬁcation, were Lp-
PLA2 (inﬂammation), neutrophil gelatinase-associated lipoca-
lin and cystatin C (both renal stress), procollagen-1-polypep-
tide (extracellular matrix remodelling), brain natriuretic
peptide, NT-proBNP, MR-proADM, soluble ST2 receptor
and copeptin (all cardiac myocyte stress), and endothelin 1
(neurohormone regulation). Gustav Smith and colleagues23
demonstrated that, in terms of predicting incident heart failure
and atrial ﬁbrillation in a general population cohort, the addi-
tion of a panel of biomarkers (mid-regional pro-atrial natri-
uretic peptide, NT-proBNP, MR-proADM, cystatin C, CRP
and copeptin) to conventional risk factors improved discrimi-
nation. The net reclassiﬁcation improvement was 22% for
heart failure and 7% for atrial ﬁbrillation. Reclassiﬁcation
was mainly achieved by the identiﬁcation of additional high-
risk individuals. In a recent review, Ketchum and Levy24 sug-
gested that risk scores had an increasing role to play among
patients with advanced heart failure whose survival has im-
proved due to therapeutic and technological advances. They
suggested that risk scores could be used to assist the selection
of patients for transplantation, left ventricle assist devices and
implantable cardioverter deﬁbrillators. Haines and col-
leagues25 recently developed a risk score to predict post-proce-
dural complications associated with the implantation of
cardioverter deﬁbrillators. The risk score was based on 10
readily available variables: age, sex, New York Heart Associa-
tion class, presence of atrial ﬁbrillation, previous valve surgery,
chronic lung disease, blood urea nitrogen, re-implantation for
reasons other than battery change, use of a dual chamber or
biventricular device and a non-elective procedure. The 4% of
the population in the highest risk category possessed an 8%
risk of complications, compared with less than 1% in the low-
est risk group.25
Studies have recently started to address whether non-inva-
sive imaging of the coronary vessels could add value to existing
risk scores.26 The coronary artery calcium score is a marker of
vascular injury and correlates well with the overall atheroscle-
rotic burden.23 Coronary CT angiography can detect non-cal-
ciﬁed plaque and indicates the severity of coronary artery
stenoses.26 Both have been shown to be of incremental value
in risk prediction among symptomatic patients, but studies
are generally lacking on the utility of incorporating them into
risk scores for use among asymptomatic people. Carotid inti-
mamedia thickness is a signiﬁcant predictor of the risk of car-
diovascular events in individuals without carotid plaques.27
When combined with information on the number of segmentswith plaque, to produce a total burden of carotid atherosclero-
sis score, the c statistic and net reclassiﬁcation index are im-
proved by 6.0% and 17.1%, respectively. The cost of
imaging is generally greater than for blood biomarkers. There-
fore, the incremental cost is likely to be prohibitive in terms of
the routine addition to general population risk scores. Cost-
effectiveness studies are required to explore whether the addi-
tional costs can be justiﬁed in a subgroup of asymptomatic
individuals identiﬁed by existing risk scores.
One of the few studies to assess the cost-effectiveness of
adding biomarkers to clinical risk scores examined patients
with stable angina who were on the waiting list for coronary
artery bypass grafting.28 They compared the status quo strat-
egy of no formalised prioritisation with prioritisation using a
clinical risk score in isolation and prioritisation after supple-
menting the clinical risk scores with additional biomarker
information using a routinely assessed biomarker (estimated
glomerular ﬁltration rate), a novel biomarker (CRP), or both.
They demonstrated that the addition of the routinely assessed
biomarker improved cost-effectiveness in terms of the net ef-
fect on lifetime costs and quality-adjusted life-years. In con-
trast, addition of the novel biomarker was not cost-effective.5. Do genetic markers add value?
Cardiovascular disease is a complex condition, with several
intermediate phenotypes, to which both environmental and ge-
netic risk factors predispose. As increasing numbers of genetic
markers have been identiﬁed, it has become increasingly clear
that the genetic component is also complex, with relatively
small contributions from a large number of genes. Therefore,
attention has focused on the development of a multilocus genet-
ic risk score that summates the overall risk from known genetic
markers. In the past couple of years, several studies have inves-
tigated whether a genetic risk score can add value to established
risk scores, some of which already include information on fam-
ily history. The studies have been undertaken in a variety of
populations but have reached consistent conclusions.
Ripatti and colleagues29 studied seven cohorts of middle-
aged men and women recruited from the general populations
in Finland and Sweden. They used published studies to iden-
tify 13 recently discovered single nucleotide polymorphisms
(SNP) associated with either myocardial infarction or coro-
nary heart disease. They constructed a multilocus genetic risk
score for each individual by summing the number of risk alleles
for each of the 13 SNP weighted by effect size. The genetic risk
score was an independent predictor of incident coronary heart
disease, cardiovascular disease and myocardial infarction
when adjusted for age, sex and traditional risk factors. In com-
parison with the lowest quintile of genetic risk score, individu-
als in the top quintile had an adjusted RR of coronary heart
disease of 1.66 (95% CI 1.35–2.04). However, addition of the
genetic risk score to traditional risk factors did not signiﬁ-
cantly improve the c statistic. There was a signiﬁcant improve-
ment in net reclassiﬁcation of people at intermediate risk (10-
year predicted risk of 10–20%) but there was no signiﬁcant
improvement in net reclassiﬁcation overall.
Paynter and colleagues30 undertook a similar study using a
cohort of white professional women in the USA. They used an
online catalogue of genome-wide association studies to identify
101 SNP shown to be associated with any form of cardiovas-
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(such as diabetes and hypertension), and derived a genetic risk
score from the sum of all risk alleles without weighting. They
also reran the analyses including only the 12 SNP shown to be
associated with cardiovascular disease. In comparison with the
lowest tertile of genetic risk score, individuals in the highest
tertile had a higher RR of cardiovascular events (RR 1.22,
95% CI 1.02–1.45) but the difference in the absolute 10-year
risk of cardiovascular disease in the top and bottom tertiles
was small (3.7% vs 3.0%). Unlike family history (which
encompasses overall inherited risk), the genetic risk score
was not signiﬁcantly associated with cardiovascular events
after adjustment for traditional risk factors. Addition of the
genetic risk score produced no signiﬁcant improvement in
either the c statistic or net reclassiﬁcation.
Qi and colleagues31 undertook a case––control study of
myocardial infarction survivors in Costa Rica. They examined
SNP associated with myocardial infarction and coronary ar-
tery disease in at least two previous genome-wide association
studies. Of the 14 SNP identiﬁed from the literature, seven
had signiﬁcant associations with the risk of myocardial infarc-
tion in their Hispanic cohort. These were used to calculate a
genetic risk score based on the sum of the risk alleles. They
demonstrated a dose relationship, whereby the risk of myocar-
dial infarction increased with increasing genetic risk score and
persisted after adjustment for traditional risk factors, including
family history. However, addition of the genetic risk score only
increased the c statistic from 0.67 to 0.68.
In common with the previous study by Paynter and col-
leagues,30 Thanassoulis and colleagues32 calculated two differ-
ent genetic risk scores: a more restrictive score derived from 13
SNP previously associated with coronary heart disease or myo-
cardial infarction, and a less restrictive score that included an
additional 89 SNP associated with intermediate phenotypes. In
both approaches, they also used both a simple and weighted
count of risk alleles. Finally, they re-ran the restrictive score
adding an additional 16 recently identiﬁed SNP. The genetic
risk scores were applied to the Framingham Offspring Cohort.
The restrictive genetic risk score performed better than the less
restrictive score and was an independent predictor of both cor-
onary heart disease and cardiovascular events. Nonetheless, it
did not improve discrimination or classiﬁcation even after
addition of the additional SNP.
These studies consistently demonstrate that, even if geno-
typic information is summarised into an overall risk score, it
does not improve the performance of existing risk scores and
therefore has no obvious clinical utility, at present, in selecting
middle-aged people for interventions. Further research is re-
quired to explore whether genetic risk scores have any role
to play in identifying the subgroup of young people who are
most likely to acquire a high-risk score in the future and, if
so, the costs, risks and beneﬁts of providing preventive inter-
ventions, such as education, to this subgroup at an earlier
stage.6. Procedure risk scores
Faroq and colleagues33,34 recently reviewed the use of risk
scores for patients undergoing coronary revascularisation.
Clinical risk scores, such as PARSONNET (Predictive score
for acquired adult heart surgery: Additive and Logistic Regres-sion models) and EuroSCORE (European System for Cardiac
Operative Risk Evaluation), have been widely adopted into
clinical practice for patients undergoing coronary revasculari-
sation. Anatomy-based risk scores, which contain no clinical
information, have been developed using information derived
from diagnostic angiography. As coronary artery grafts are
used to bypass stenoses and the anastomoses are positioned
distal to the diseased segment, additional anatomical informa-
tion does not signiﬁcantly improve the performance of clinical
risk scores among patients being managed surgically. In con-
trast, the severity, length and distribution of stenoses are crit-
ical to the selection and outcome of patients undergoing PCI.
Anatomy-based scores, such as SYNTAX (SYNergy between
PCI with TAXus and surgery), have been shown to be predic-
tive of clinical outcomes following PCI,35 but visual interpreta-
tion of coronary angiograms is subject to interobserver
variation. Therefore, functional anatomy-based scores, which
incorporate objective information from fractional ﬂow reserve
or quantitative coronary angiography, have better prognostic
ability.
More recently, a number of risk scores have been developed
that combine clinical and anatomical information.36–42 The
Euro-Heart score is constructed from 12 clinical characteristics
and four lesion characteristics. It was developed and validated
on the 46,064 patients recruited to the EuroHeart Survey of
PCI and performed well at identifying patients at risk of in-
hospital death, producing a c statistic of 0.90.36 The Clinical
SYNTAX Score (CSS) combines the anatomically derived
SYNTAX score with a modiﬁed version of the clinical ACEF
(Age, Creatinine and Ejection Fraction) score. Patients in the
highest tertile of CSS had higher rates of repeat revascularisa-
tion (21%) and major adverse cardiac and cerebrovascular
events (MACCE) (32%) over 1-year following PCI, with evi-
dence of a dose relationship across the tertiles.37 The CSS
had a higher i statistic than either the SYNTAX score or
ACEF score used in isolation in relation to predicting both
MACCE and all-cause death.37 Capodanno and colleagues38
compared two combined clinical/anatomical risk scores (The
Global Risk Classiﬁcation and the Clinical SYNTAX risk
score), two clinical risk scores (ACEF and EuroSCORE) and
one anatomy-based risk score (SYNTAX) among patients
with left main stem stenosis undergoing either PCI or coronary
artery bypass grafting. The best predictive characteristics were
obtained using a clinical risk score (ACEF) for surgical pa-
tients compared with a combined clinical/anatomical risk score
(GRC) for PCI. Similarly, Chen and colleagues39 compared
the combined clinical/anatomical NERS (New Risk Stratiﬁca-
tion Score) with the CSS in terms of predicting the risk of
MACCE over 6 months follow-up, among patients in whom
coronary stents were implanted for left main stem stenoses.
In comparison with the clinical risk score, the combined score
had both higher sensitivity and higher speciﬁcity.39 Chakrav-
arty and colleagues40 also examined patients treated by surgery
or PCI for left main stem disease. They compared the perfor-
mance of a combined risk score, produced by combining the
PARSONNET and SYNTAX risk scores, with using the lat-
ter, an anatomical risk score, in isolation. Patients were fol-
lowed up for a median of 3 years. The study suggested that
using anatomical information in isolation did not predict out-
come following surgery. In contrast, the SYNTAX risk score
was predictive among patients undergoing PCI but could be
improved by the addition of clinical information.
10 J.P. PellMany of the risk scores developed for use in patients under-
going coronary revascularisation predated the widespread
adoption of drug-eluting stents and, therefore, perform less
well in these patients than in those undergoing balloon angio-
plasty. Stolker and colleagues43 recently developed and vali-
dated a risk score that combined clinical, procedural and
anatomical information using the EVENT (Evaluation of
Drug Eluting Stents and Ischaemic Events) Registry, and eval-
uated its ability to predict target lesion revascularisation at 1-
year follow-up. The relatively simple score was composed of
only six variables: age, previous PCI, left main PCI, saphenous
vein graft location, minimum stent diameter and total stent
length. The investigators demonstrated a threefold difference
in target lesion revascularisation between the highest risk
and lowest risk categories (7.5% vs 2.2%).7. Conclusion
Cardiovascular risk scores have existed for many years but
they are still subject to new and interesting research. They
are increasingly being applied to conditions other than coro-
nary heart disease, such as type II diabetes and heart failure,
which are of increasing importance for public health. New bio-
markers have been identiﬁed that improve discrimination but,
inevitably, the marginal beneﬁt decreases with each additional
predictor. Also, improved discrimination needs to be weighed
against increased cost and complexity, especially when risk
scores are applied to the general population. As highlighted
in a recent Heart editorial, ease of use has a major impact
on the implementation of risk scores.3 Recent research has fo-
cused on identifying new biomarkers and evaluating their
effectiveness, but there is a paucity of applied research on
cost-effectiveness and coverage. This needs to be addressed.
The conclusions may differ depending on the location in which
risk scores are being measured and the subgroup of the popu-
lation to which they are applied. To date, there is no evidence
that genetic markers improve risk prediction when used in
middle-aged populations. If they have a role to play, it may
be in younger people in whom traditional risk scores are of lit-
tle value. Another approach to identifying at-risk individuals
at a younger age is lifetime risk. Irrespective of the approach
adopted, the cost-effectiveness of earlier screening and inter-
vention needs to be properly evaluated.
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